Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk

Subha Subramanian, Chunyu Liu, Abraham Aviv, Jennifer E. Ho, Paul Courchesne, Pieter Muntendam, Martin G. Larson, Susan Cheng, Thomas J. Wang, Nehal N. Mehta, Daniel Levy

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - CXCL12 encodes stromal cell-derived factor 1α (SDF-1), which binds to the receptor encoded by CXCR4. Variation at the CXCL12 locus is associated with coronary artery disease and endothelial progenitor cell numbers, whereas variation at the CXCR4 locus is associated with leukocyte telomere length, which has been shown to be associated with coronary artery disease. Therefore, we examined the relationships of plasma SDF-1 levels to cardiovascular disease (CVD)-related outcomes, risk factors, leukocyte telomere length, and endothelial progenitor cells. APPROACH AND RESULTS - SDF-1 was measured in 3359 Framingham Heart Study participants. We used Cox regression to examine relationships of SDF-1 to new-onset CVD, myocardial infarction, heart failure, and all-cause mortality; we used linear regression to evaluate associations of SDF-1 with risk factors, leukocyte telomere length, and CD34cell phenotypes. In multivariable models, higher SDF-1 levels were associated with older age, lower levels of high-density lipoprotein-cholesterol and cigarette smoking. Higher SDF-1 levels were associated with lower CD34cell frequency (P=0.02) but not with leukocyte telomere length. During follow-up (median, 9.3 years), there were 263 new-onset CVD events, 160 myocardial infarctions, 200 heart failure events, and 385 deaths. After adjusting for clinical risk factors, SDF-1 levels were associated with heart failure (P=0.04) and all-cause mortality (P=0.003) but not with CVD (P=0.39) or myocardial infarction (P=0.10). The association of SDF-1 levels with myocardial infarction was attenuated after adjustment for high-density lipoprotein-cholesterol. CONCLUSIONS - After adjusting for traditional CVD risk factors, SDF-1 is associated with heart failure and all-cause mortality risk. Additional studies are needed to determine whether measurement of SDF-1 levels has clinical use.

Original languageEnglish (US)
Pages (from-to)2100-2105
Number of pages6
JournalArteriosclerosis, thrombosis, and vascular biology
Volume34
Issue number9
DOIs
StatePublished - Sep 2014
Externally publishedYes

Keywords

  • cardiovascular diseases
  • chemokine CXCL12
  • epidemiology
  • heart failure
  • mortality
  • myocardial infarction
  • stem cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk'. Together they form a unique fingerprint.

  • Cite this

    Subramanian, S., Liu, C., Aviv, A., Ho, J. E., Courchesne, P., Muntendam, P., Larson, M. G., Cheng, S., Wang, T. J., Mehta, N. N., & Levy, D. (2014). Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arteriosclerosis, thrombosis, and vascular biology, 34(9), 2100-2105. https://doi.org/10.1161/ATVBAHA.114.303579